JORGE E CORTES to Tretinoin
This is a "connection" page, showing publications JORGE E CORTES has written about Tretinoin.
Connection Strength
0.761
-
A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Leukemia. 1997 Jul; 11(7):929-32.
Score: 0.120
-
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol. 2015 Nov; 171(4):471-7.
Score: 0.105
-
Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e47-9.
Score: 0.093
-
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007 Oct 01; 110(7):2302-8.
Score: 0.060
-
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer. 2007 Apr 01; 109(7):1355-9.
Score: 0.059
-
Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood. 2005 Feb 01; 105(3):1366-7.
Score: 0.051
-
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002 Jun 01; 99(11):4222-4.
Score: 0.042
-
Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid. Leuk Lymphoma. 2001 Jul; 42(3):309-16.
Score: 0.040
-
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. Leuk Lymphoma. 1999 Nov; 35(5-6):483-9.
Score: 0.035
-
Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood. 1999 Oct 01; 94(7):2230-5.
Score: 0.035
-
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999 Apr 15; 93(8):2478-84.
Score: 0.034
-
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53.
Score: 0.025
-
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Cancer. 2012 Dec 01; 118(23):5811-8.
Score: 0.021
-
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer. 2011 Jan 01; 117(1):110-5.
Score: 0.019
-
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 01; 27(4):504-10.
Score: 0.017
-
Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 1995 Feb 15; 85(4):1083-94.
Score: 0.006